Consumer health and hygiene company RB plc, formerly called Reckitt Benckiser, has revealed that it will establish a research and development center in the north of England.
The company will invest £100 million to build the facility as part of plans to grow its global consumer health business.
The availability of effective self-medication is a critical part of the growing socio-economic need to help people manage their health, commented Rakesh Kapoor, RB Global CEO.
Located at its existing site in Hull, the Centre of Scientific Excellence will be one of six major R&D facilities operated by RB around the world. It will serve as the global technical innovation hub for products such as Nurofen and Strepsils.
In a statement announcing its investment, RB said that it chose the Hull site following a review that considered RB's other R&D locations. The decision reflects the UK's consumer health expertise as well as the UK government's positive attitude towards encouraging innovation, science and technology, it said.
To help fund the project, RB has been granted £6 million from the UK Regional Development Fund. Design and planning work for the new building is under way and construction work is expected to start early next year. The center, complete with state of the art consumer health laboratory facilities, will be fully operational by early 2018.
RB's health, hygiene and home brands include Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Lysol, MegaRed, Dettol, Veet, Harpic, Bang, Veja, Mortein, Finish, Vanish, Calgon, Air Wick and French's.